Clinuvel Pharmaceuticals

CUV.AXApproved

Clinuvel Pharmaceuticals is a global leader in photomedicine, translating scientific expertise in melanocortins into therapeutic and cosmetic solutions. The company's core focus is on developing treatments for severe photodermatoses, vitiligo, and exploring applications in DNA repair and central nervous system disorders. With a commercial-stage product generating record revenues, Clinuvel is strategically expanding its pipeline and luxury skincare division, PhotoCosmetics, to leverage its proprietary science across multiple markets.

Market Cap

$338.6M

Focus

Small Molecules

CUV.AX · Stock Price

USD 9.647.88 (-44.98%)

Historical price data

AI Company Overview

Technology Platform

World-leading expertise in melanocortin hormones, particularly α-MSH and its analogue afamelanotide, which modulate pigmentation, DNA repair, inflammation, and central nervous system function via melanocortin receptors (MC1R-MC5R).

Pipeline Snapshot

23 drugs in pipeline, 6 in Phase 3

Drug	Indication	Stage
Afamelanotide and NB-UVB Light	Vitiligo	Phase 3
Afamelanotide	Erythropoietic Protoporphyria	Phase 3
Afamelanotide + Placebo	Erythropoietic Protoporphyria	Phase 3
Afamelanotide + Placebo	Polymorphic Light Eruption	Phase 3
Afamelanotide + Placebo	Erythropoietic Protoporphyria	Phase 3

Funding History

Total raised: $30M

PIPE$25MUndisclosedJun 15, 2019

IPO$5MUndisclosedOct 20, 2005

FDA Approved Drugs

SCENESSENDAOct 8, 2019

Opportunities

Significant growth opportunities exist in expanding afamelanotide's label into larger markets like vitiligo and exploring its DNA repair properties in XP.

The PhotoCosmetics division offers a high-margin avenue to monetize core technology in the expansive luxury skincare market, providing revenue diversification.

Risk Factors

Key risks include clinical trial failures in pipeline expansion efforts (vitiligo, stroke), over-reliance on a single commercial product (SCENESSE®) in a niche orphan disease market, and the challenge of successfully competing in the crowded consumer skincare space with the PhotoCosmetics line.

Competitive Landscape

In its core EPP market, Clinuvel holds a monopoly with SCENESSE®. In pipeline areas like vitiligo, it will face competition from JAK inhibitors and phototherapy. Its DNA repair program is highly novel with no direct competitors. The PhotoCosmetics line competes on scientific branding in a crowded premium skincare market.

Publications

Patents

Pipeline

FDA Approvals